MTVA: Phase 1 Part 2 Data for DA-1726 in Obesity Expected Soon
On March 20, 2025, MetaVia Inc. (MTVA) announced financial results for 2024 and provided a business update. We anticipate topline results from the...
254 Views
MTVA: Compelling Data for DA-1241 in Phase 2a MASH Trial
On December 18, 2024, MetaVia announced positive topline results from the Phase 2a clinical trial of DA-1241 in patients with presumed metabolic...
456 Views
Dong A St (170900 KS): Five Reasons Why Performance Improvement Is Expected
​Dong A St sees double-digit revenue growth in 1Q25. Strong existing operation and forthcoming launches to fuel growth. Pipeline is promising, with...
269 Views
MTVA: NeuroBo Becomes MetaVia Topline Results for Phase 2a
n November 18, 2024, NeuroBo Pharmaceuticals, Inc. (NRBO) announced a strategic realignment with a name change to MetaVia Inc. (MTVA).
324 Views
NRBO: Topline Results for Phase 2a Trial of DA-1241 in MASH Expected in December 2024
On November 7, 2024, NeuroBo Pharmaceuticals, Inc. (NRBO) announced financial results for the third quarter of 2024 and provided a business...
145 Views